Danaher Names Matthew Gugino as New CFO, Matthew McGrew to Transition to Executive Vice President

Danaher Corporation announced that Matthew Gugino will succeed Matthew McGrew as CFO effective February 28th, 2026. McGrew will continue as Executive Vice President after a 20-year tenure with Danaher. Gugino has been Group CFO of the Life Sciences Innovations Group and VP of Financial Planning & Analysis since 2021. Prior to Danaher, he worked at Barclays and Morgan Stanley, and at KPMG.

Danaher Corporation (NYSE: DHR) has announced that Matthew Gugino will succeed Matthew McGrew as Chief Financial Officer (CFO), effective February 28, 2026. Gugino currently serves as Group Chief Financial Officer of the company’s Life Sciences Innovations Group and Vice President of Financial Planning & Analysis. Following the transition, McGrew will continue as an Executive Vice President as he begins a gradual transition to retirement after more than 20 years with the company [1].

Gugino joined Danaher in 2013 as Director of Investor Relations and has held various leadership positions within the company. Prior to joining Danaher, he worked at Barclays, Morgan Stanley, and KPMG. He holds accounting degrees from Villanova University. McGrew has served as Danaher’s CFO since January 2019, having joined the company in 2004. During his tenure as CFO, the company nearly doubled both its revenue and market capitalization, with current annual revenue reaching $23.82 billion. The company maintains strong financial metrics, with a gross profit margin of 59.8% and consistent dividend payments for 33 consecutive years [1].

"Matt McGrew’s financial leadership over the past two decades has been instrumental in shaping the Danaher you see today," said Rainer Blair, President and Chief Executive Officer, in the announcement. Danaher, which describes itself as a global life sciences and diagnostics innovator, employs approximately 63,000 people worldwide [1].

The planned transition represents a continuation of Danaher’s leadership succession strategy, with the company providing a seven-month notice period before the official change takes place. In other recent news, Danaher Corporation has reported significant developments in its business operations and strategic partnerships. The company recently announced its first-quarter 2025 results, showing strong performance in its Biotechnology segment, which achieved core growth at the high end of guidance. Danaher has also raised its 2025 bioprocessing outlook to high-single-digit growth, driven by strong consumables performance [1].

Danaher has made strategic leadership appointments, including Martin Stumpe as Chief Technology and AI Officer and Greg Milosevich as Executive Vice President of Life Sciences. These appointments are part of Danaher’s ongoing efforts to enhance its digital transformation and strengthen its leadership in the life sciences sector. In another strategic move, Danaher has partnered with AstraZeneca to develop advanced AI-driven diagnostic tests aimed at improving precision medicine. This collaboration will focus on digital and computational pathology products to enhance patient diagnosis and treatment selection [1].

References:
[1] https://www.investing.com/news/company-news/danaher-names-matthew-gugino-as-next-cfo-in-planned-transition-93CH-4145347
[2] https://www.marketwatch.com/story/danaher-names-gugino-as-cfo-succeeding-mcgrew-1025bcbb
[3] https://www.marketscreener.com/news/danaher-appoints-matthew-gugino-as-finance-chief-ce7c5cdcd18cf526